Pharmatalkradio

Medical research charities in the UK have been successfully integrating patient insight into their activities for over 10 years. In this session presented at the 2nd annual Patients as Partners Europe in January 2018, Claire Nolan, Research Involvement Manager, Parkinson's UK, and Chris MacDonald, Research Involvement Manager, Arthritis Research UK, explore a shift in attitiude towards pharmaceutical and medical research charity collaboration. They share how charities have developed their processes to strike a balance of delivering effective research outcomes whilst ensuring principled and meaningful patient involvement and how these experiences, resources, and processes can be used practically to support industry to put the needs and voice of patients at the centre of medicines development. The 3rd annual Patients as Partners Europe will be presented January 28-29, 2019 in London, UK. Find more information here.

This 5 minute podcast summarizes what you can expect at the 3rd annual Patients as Partners EU conference. It is the only event in Europe that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. It takes place January 28-29 at the Millennium Gloucester Hotel in the Kensington area of London. The program is co-chaired by GSK's  Andrew Garvey, Global Patient Advocacy Lead and Servier's Dr Lode Dewulf, Chief Patient Officer. The conference kicks off with former professional English footballer and patient advocate, Geoff Thomas, in a keynote presentation on his journey through professional sports and his fight against cancer.  For more information please contact www.theconferenceforum.org or contact us at service@tcfllc.org.  

In this talk from the 5th annual Patients as Partners US conference, Beth Zaharoff, Director, Patient-Focused Clinical Trial Engagement of Tesaro will walk the audience through how they integrated patient input throughout multiple stages of the development process. Other discussion points include: How Tesaro is working to eliminate some of the burdens inherent in clinical trial participationWhat patient focus means to Tesaro and why/how they decided to jump in the deep endTesaro focus groups and what they learned from the experts Join us this year at the 6th annual Patients as Partners US conference, taking place March 11-12, 2019 in Philadelphia.

Originally recorded at the 4th annual Immuno-Oncology 360° 2018 event, Dr Corey Langer, Director, Thoracic Oncology and Professor of Medicine for the Perelman Center for Advanced Medicine at the University of Pennsylvania, discusses data on Keytruda in combination with chemotherapy in non-small cell lung cancer. This year, the University of Pennsylvania will be represented by Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies. Dr Ruella will be discussing the next steps for CAR-T therapy for cancer on day three during the Next Generation Cell Therapy Plenary To join in on the discussion at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY!

In this podcast, originally recorded at the 4th annual annual Immuno-Oncology 360° 2018 event, Dr Axel Hoos, SVP, Oncology R&D, GSK, led a panel on The Future Value Generation in IO. Dr Hoos was joined by expert analyst Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research for Citi along with Dr David Grayzel, Partner of Atlas Venture, Dr Simeon George, Partner of SR One and Mark Simon, Partner of Torreya Partners. Key discussion points included: What is the most important IO event or trend that will carry us forward and shape the IO space?With the ever expanding range of indications, what is next and how do we get there?What have we learned from precision medicine and how can that be applied to IO?Which biomarker is next that will follow PDL1 and that will help guide the field in patient selection?With the many opportunities now with modalities, what do you think is a valuable next modality that could be important?With the maturing and evolving IO landscape, has that changed

Greg Simon, President at the Biden Cancer Initiative and Former Executive Director of the White House Cancer Task Force will reflect on the work of the Cancer Moonshot. Which provided the leadership to harness the millions of scientists and patients, powerful new therapies, and cultural changes needed to double our rate of progress against cancer.  He will also provide a progress report on the Biden Cancer Initiative which is now continuing this movement to double our rate of progress in preventing, detecting, diagnosing and treating cancer. This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018. For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.

Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including: The need to educate physicians about management of immune related adverse events with increasing penetration of checkpoint inhibitors into the communityThe relationship of these adverse events to outcome with checkpoint inhibitionThe relation of adverse events to other autoimmune diseases that are similar in nature This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018. For more information on the IO360 conference and details for the 5th annual program taking place February 6-8, 2019 in New York, NY, please visit io360summit.com. 

The BioCentury Report on Industry Trends covers how companies and academic investigators are driving innovations within immuno-oncology, including new targets, modalities and technologies, to address some of the field's biggest challenges. Some topics include: The broadening trend to harness the innate and adaptive arms of the immune system for immunotherapiesNew cell types beyond CAR-T and traditional T-cellsCombination strategies for neoantigens and other targets from the earliest stages of drug development This presentation, presented by Simone Fishburn, PhD, Editor, BioCentury Innovations, was given at the 4th Annual Immuno-Oncology 360° Event on February 7-9, 2018 in New York City. Find more information at io360summit.com

IO360° brings together science, clinical and business under one roof to accelerate treatments to fight a wider range of cancers. This brief podcast gives you an overview on what you can expect at IO360°. The three-day summit features 10 plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees. Key benefits: Access to KOLs driving the sciencePartnership opportunities with all stakeholders in Immuno-OncologyPresentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology IO360° is chaired by Dr Andrew Baum, Citi along with Dr Axel Hoos, GlaxoSmithKline and Dr James Gulley, National Cancer Institute. Learn more information about IO360° at www.io360summit.com Take 10% off the regitration fee with code RADIO

The 8th Annual Partnership Opportunities in Drug Delivery (PODD) event will take place on October 18-19, 2018. PODD is designed with 3 purposes: To present a strategic level program for pharma and biotech biz development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities.To provide drug delivery with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones. PODD is chaired by Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche. MIT's Dr Robert Langer and Polaris' Amy Schulman, two dynamic entrepreneurs in biotech are the opeining keynotes in a fireside chat. Justin Wright, PhD, Global Head of Innovation, Novartis will provide an industry keynote.  Also, Jeffrey Karp, PhD keynotes with Stories from Bioinspi

Can you imagine coming from a family of 21 kids in a small remote village in Africa with no running water or electricity and one day a snake bite changes your entire future and you end up a PhD student in WInston-Salem, NC?  In this remarkable story, our guest Goodwell Nzou, PhD candidate in molecular medicine at the Institute at Wake Translation Science tells Valerie Bowling, Executive Director, the Conference Forum how he went from a village kid to an amputee to a band member that led him to a contest, a role in an Oscar winning documentary to a PhD candidate in a field that he hopes one day will allow him to grow back his own leg through regenerative medicine.  Schools cited in the podcast include: Jairos Jiri Association  King George VI Centre Wake Forest School of Medicine Guest: Goodwell Nzou, PhD candidate in molecular medicine at the Inst at Wake Translation Science Host: Valerie Bowling, Executive Director, PharmaTalk Radio and the Conference Forum 

Podcast guest, Elise Felicione, who is currently a Scientific Collaborator at the Scripps Translational Science Institute is playing an integral role under the direction of Dr Eric Topol on a nation-wide initiative from the NIH. The initiative is called All Of Us, a US Precision Medicine program that aims to enroll a million Americans and follow them for 10 years, during which time participants will contribute biological, environmental, and lifestyle data.  One-third of participants will participate virtually (not via a research site).  The cohort will mirror the projected 2040 census. Individual pharma companies are never going to create cohorts like this, so the importance of this open source frame work that drug developers can tap into will be highly beneficial in serving the patient of the future. Discussion points include: What is the All Of Us Research Program?Why does this matter to biopharmaceutical companies?How far along is the program and how to get invovled?What are your biggest challenges?How ca

During his graduate work, Dr Benjamine Liu observed the many bottlenecks that get in the way of clinical trials slowing the development of new treatments for patients. This challenge inspired him to launch Trialspark. Trialspark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 98% of patients and doctors not involved in trials today and democratizing access to research treatments.  In this podcast discussion with Ben, we discuss how to reimagine clinical trials, entrepreneurism, the rise of Trialspark and reducing the barriers for patients and investigators.  Ben will be speaking at DPharm on September 26th in Boston with Dr Ulo Palm, SVP Global Drug Development Operations, Allergan on a case study to scale more efficient clinical trials. For more information about Trialspark, visit www.trialspark.com For more information about DPharm visit www.theconferenceforum.org Producer: Valerie Bowling, Executive Director, Pharma Talk Radio and

Patients are at the center of research and their data is the foundation for clinical innovation. However, significant barriers exist that inhibit the secure and efficient sharing of patient data. In this podcast, Craig Lipset, Head of Clinical Innovation, Pfizer, Munther Barra, Head of New Clinical Paradigm, Pfizer and Aditya Kudumala, Principal, Deloitte discuss blockchain as a catalyst to significantly change how we can access and use data to improve patient lives. Where is the patient data storm going? Discussion points include, but not limited to: Who owns my data and where it’s going?What are the interoperability challenges and progress?How can data be shared?How you can pull in your own health data?Where does blockchain fit in and how can it secure patient data?  How blockchain gives us authentication without identification?Next steps?  For more information on this topic and to get access to the Blockchain Opportunities for Patient Data Donation & Cinical Research, click here.  Craig will be leadi

This 8 minute podcast gives you an overview on what to expect from the 8th annual DPharm conference. DPharm is the annual event in the US to get the best access to innovative ideas, especially disruptive ones, to advance clinical trials with a view to reducing the burden to patients and investigators. DPharm 2018 is dedicated to all things digital, data science, patient data ownership and new approaches to optimize clinical operation systems. DPharm is September 25-26 at the Boston Marriott Copley Place. Chaired by: Sylke Poehling, PhD, SVP and Global Head, Strategy, Portfolio & Clinical Operations, Pharma Research & Early Development, Roche Andreas Koester, MD, PhD, VP and Global Head, Janssen Clinical Innovation, Janssen Craig Lipset, MBA, Head of Clinical Innovation, Pfizer For more information visit www.theconferenceforum.org Producer: Valerie Bowling, Executive Director, DPharm    

Welcome to the 5th annual Mobile in Clinical Trials podcast. In this quick fire podcast, you will get a brief overview on what to expect. The conference takes place in Boston on Sept 24th, the day before DPharm. It is researched and produced by the Conference Forum and is chaired by:  Daniel Karlin, MD Assistant Professor of Psychiatry, Tufts University and Former Head of Clinical, Informatics, and Regulatory Strategy, Digital Medicine, Pfizer Inc Mobile and digital tools are the future of clinical trials and as the industry continues to transition into a data science industry with a responsibility to reduce patient burden, it is really important that we bring this conference to you to get the latest examples on what tools are available and who has used them and what are the lessons to engage patients? For more information, visit www.theconferenceforum.org Producers: Valerie Bowling, Executive Director, the Conference Forum and Jennifer Moran, Producer, the Conference Forum        

Rational Combinations 360° addresses business aspects, clinical advancements and scientific data in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune system to eradicate cancer. Rational Combinations 360° addresses the following plenary topics over the course of 2 days: Discovery and Preclinical ScienceTranslational Science and Emerging BiomarkersOperationalizing IO CombinationsEmerging Clinical CombinationsEmerging Data Combinations in Clinical TrialsBusiness Aspects Dr Patrick Hwu, MD Anderson, Dr Axel Hoos, GSK and Dr Ian McCaffery, Janssen, together led the design of the 3rd annual program that includes more than 45 speakers and over 30 talks. For more information about Rational Combinations 360°, visit, www.theconferenceforum.org. Be sure to use code TEML for a

How to Innovate in the Drug Delivery Space What does the innovation process look likeThe barrier to the innovation process and how to overcomethemSummary of disease spaceGood design and engineering practicesHow to salvage something that goes wrong?How do you find the unknown unknowns?Does it feel right? Uri Baruch Head of Drug Delivery, Cambridge Design Partnership This talk was given at the 2018 Drug Delivery West Meeting.

Opening talk at Drug Delivery West, 2018 Key Trends in Drug Delivery: Expert Perspective Randall Mrsny, PhD Professor's Chair, Department of Pharmacy and Pharmacology, University of Bath

Patients as Partners Day 2 Session How FARA and Horizon Pharma Partnered to Improve Clinical Development and Trial Design-Case Study This session will feature how the Friedreich’s Ataxia Research Foundation collaborated with Horizon Pharma on aspects of clinical development and trial design to better understand patients living with the disease and how to better develop medicine to help manage their disease. Key areas of discussion include how they collaborated on the following: • Focus groups to better understand drug administration • Clinical trial design to ensure feasibility and efficiency • Recruiting patients for clinical trials • Open discussion at FDA meetings Kyle Bryant Director of the Bicycle Ride Fundraiser, rideAtaxia for the Friedreich’s Ataxia Research Alliance (FARA)  Robert Metz SVP, Global Business Operations and External Affairs, Horizon Pharma